IN2015DN04151A - - Google Patents

Info

Publication number
IN2015DN04151A
IN2015DN04151A IN4151DEN2015A IN2015DN04151A IN 2015DN04151 A IN2015DN04151 A IN 2015DN04151A IN 4151DEN2015 A IN4151DEN2015 A IN 4151DEN2015A IN 2015DN04151 A IN2015DN04151 A IN 2015DN04151A
Authority
IN
India
Prior art keywords
same
formulations
compositions
methods
acid esters
Prior art date
Application number
Inventor
Dechi Guan
David I Macdonald
Original Assignee
Methylation Sciences Internat Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylation Sciences Internat Srl filed Critical Methylation Sciences Internat Srl
Publication of IN2015DN04151A publication Critical patent/IN2015DN04151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

Provided herein are compositions and formulations comprising S adenosyl L methionine ('SAM e' or 'SAMe') and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters.
IN4151DEN2015 2012-10-17 2013-10-16 IN2015DN04151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715138P 2012-10-17 2012-10-17
PCT/CA2013/000876 WO2014059522A1 (en) 2012-10-17 2013-10-16 Compositions comprising s-adenosylmethionine and a gallic acid ester

Publications (1)

Publication Number Publication Date
IN2015DN04151A true IN2015DN04151A (en) 2015-10-16

Family

ID=50487370

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4151DEN2015 IN2015DN04151A (en) 2012-10-17 2013-10-16

Country Status (15)

Country Link
US (6) US9801896B2 (en)
EP (2) EP2753336B1 (en)
JP (2) JP5877935B2 (en)
KR (2) KR20160094451A (en)
CN (2) CN104884067B (en)
AU (1) AU2013332209B2 (en)
CA (1) CA2888302C (en)
DK (1) DK2753336T3 (en)
ES (1) ES2540581T3 (en)
HK (2) HK1199836A1 (en)
IL (1) IL243585A0 (en)
IN (1) IN2015DN04151A (en)
RU (2) RU2586300C1 (en)
SG (1) SG11201503048TA (en)
WO (1) WO2014059522A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840472B2 (en) 2016-05-03 2023-12-12 Heraeus Quartz North America Llc Elongation method and preform for producing an optical glass component

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059522A1 (en) 2012-10-17 2014-04-24 Methylation Sciences International Srl Compositions comprising s-adenosylmethionine and a gallic acid ester
CN106714810A (en) * 2014-04-14 2017-05-24 甲基化物科学国际有限公司 Novel ademetionine formulations
RU2587331C1 (en) * 2015-06-19 2016-06-20 Общество с ограниченной ответственностью "Полигепазол" Method of producing pharmaceutical composition ademetionine and dosage form thereof
CN105232515A (en) * 2015-10-10 2016-01-13 齐齐哈尔医学院 Application of ethyl gallate for preparing drugs for treating human colon carcinoma cell apoptosis
CN105476982A (en) * 2016-02-02 2016-04-13 张干 New application of gallic acid
CN108853085A (en) * 2017-05-15 2018-11-23 苏州凯祥生物科技有限公司 Catechin and epicatechin class compound are used to raise the purposes of MicroRNA-126 expression
CN111265509A (en) * 2020-02-19 2020-06-12 齐鲁工业大学 Application of gallic acid derivative in preventing and treating atherosclerosis diseases
CN114931571A (en) * 2022-03-30 2022-08-23 上海中医药大学附属曙光医院 Application of gallic acid methyl ester in preparation of osteoarthritis treatment medicine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37913B1 (en) 1972-08-02 1977-11-09 Bioresearch Sas Salt of s-adenosyl-l-methionine
IT1173992B (en) 1984-05-16 1987-06-24 Bioresearch Spa STABLE SALTS OF SULPHO-ADENOSYL-METHIONINE (SAME) PARTICULARLY SUITABLE FOR ORAL PHARMACEUTICAL USE
FR2623396B1 (en) 1987-11-25 1990-03-30 Sanofi Sa USE OF ADEMETIONINE AGAINST AGING SKIN
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
JPH05271067A (en) 1992-03-24 1993-10-19 Takeda Chem Ind Ltd Fibrosis-suppressing agent
RU2018314C1 (en) * 1993-07-15 1994-08-30 Приморское научное медико-техническое общество Agent for treatment of eczema
DE19631085A1 (en) 1996-08-01 1998-02-05 Basf Ag Use of (meth) acrylic acid-maleic acid copolymers to improve the permeability of the mucosa
US6180666B1 (en) * 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
FI113942B (en) * 2000-08-18 2004-07-15 Control Ox Oy Use of Vegetable Phenolic Compounds in the Manufacture of Pharmaceutical Preparation Useful in the Treatment and Prevention of Chlamydia Infection, Nutritional Benefits or Composition for Addition to Such Foods
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6759395B2 (en) 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US8263574B2 (en) 2004-09-29 2012-09-11 James L. Schaller, P.A. Topical formulations for the treatment of depression with S adenosyl methionine
GB0603252D0 (en) 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
US20070265211A1 (en) * 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
US20100056627A1 (en) 2006-12-28 2010-03-04 Tomihiko Higuchi Pharmaceutical compositions of alkyl gallates
CN101012336A (en) * 2007-01-31 2007-08-08 浙江大学 High-strength degradable cereal protein plastics containing plant oil and preparing method thereof
CA2677053C (en) 2007-01-31 2016-03-15 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2010012109A1 (en) 2008-08-01 2010-02-04 Volkovs System and method for the calculation of a polynomial-based hash function and the erindale-plus hashing algorithm
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2012012902A1 (en) * 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20130004563A1 (en) 2011-06-07 2013-01-03 Shah Syed Multiparticulate s-adenosylmethionine compositions and related methods
WO2014059522A1 (en) 2012-10-17 2014-04-24 Methylation Sciences International Srl Compositions comprising s-adenosylmethionine and a gallic acid ester

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840472B2 (en) 2016-05-03 2023-12-12 Heraeus Quartz North America Llc Elongation method and preform for producing an optical glass component

Also Published As

Publication number Publication date
AU2013332209A1 (en) 2015-05-28
US20140220129A1 (en) 2014-08-07
SG11201503048TA (en) 2015-06-29
JP2015533367A (en) 2015-11-24
CN104884067B (en) 2016-09-07
AU2013332209B2 (en) 2016-02-04
RU2586300C1 (en) 2016-06-10
ES2540581T3 (en) 2015-07-10
IL243585A0 (en) 2016-02-29
US20150283161A1 (en) 2015-10-08
JP2016074725A (en) 2016-05-12
US9925208B2 (en) 2018-03-27
KR20150104559A (en) 2015-09-15
CA2888302A1 (en) 2014-04-24
US20190022119A1 (en) 2019-01-24
CN106074589A (en) 2016-11-09
DK2753336T3 (en) 2015-07-27
WO2014059522A1 (en) 2014-04-24
EP2753336A4 (en) 2014-09-03
HK1217909A1 (en) 2017-01-27
US20220193107A1 (en) 2022-06-23
US20200129537A1 (en) 2020-04-30
EP2753336B1 (en) 2015-05-06
CN104884067A (en) 2015-09-02
RU2016117290A (en) 2018-10-23
JP6280535B2 (en) 2018-02-14
KR101748053B1 (en) 2017-06-15
US20150164935A1 (en) 2015-06-18
US8975238B2 (en) 2015-03-10
HK1199836A1 (en) 2015-10-09
EP2753336A1 (en) 2014-07-16
KR20160094451A (en) 2016-08-09
CA2888302C (en) 2016-05-31
JP5877935B2 (en) 2016-03-08
US9801896B2 (en) 2017-10-31
EP2949331A1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
IN2015DN04151A (en)
WO2014004993A3 (en) Methods of reducing ldl-p
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
MX370543B (en) Vegf neutralizing prodrugs for the treatment of ocular conditions.
MX2022010507A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
IN2015DN00376A (en)
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX349992B (en) High concentration alpha-glucosidase compositions for the treatment of pompe disease.
AR091006A1 (en) PROLIPOSOMAL TESTOSTERONE FORMULATIONS
NZ702799A (en) Methods and compositions for cns delivery of arylsulfatase a
MX350666B (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia.
IN2014DN00277A (en)
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
MX2015015036A (en) Methods for improving lipid profiles using atrasentan.
MX2016015211A (en) Topical formulations and uses thereof.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
EP3309555A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
IN2014CN04009A (en)
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
BR112015002384A8 (en) pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and, optionally, a pi3k-alpha inhibitor, and their uses.
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
BR112013026363A2 (en) nanosuspensions of freeze-dried drug
UA64817U (en) method for treatment of patients with syndrome of increased fatigue using apipreparations
MX357329B (en) Raw extract of a sechium edule hybrid, method for extracting same and use thereof for formulations having an antineoplastic effect.